Orexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
Orexo AB (OTCQX: ORXOY) has partnered with Trinity Health to enhance patient access to its digital therapeutics, vorvida® and deprexis®. The collaboration establishes a collaborative care model, educating over 50 healthcare professionals to integrate these therapies, which aim to assist patients dealing with depression and excessive drinking. Trinity Health serves over 200,000 people across North Dakota and Eastern Montana, addressing significant mental health and substance use issues in these regions. This partnership marks a significant step in expanding access to evidence-based psychosocial support.
- Partnership with Trinity Health expands access to digital therapeutics for mental health.
- Over 50 healthcare professionals trained to support the integration of digital therapies.
- Addresses high rates of depression and substance use in North Dakota and Montana.
- None.
UPPSALA, Sweden, Sept. 7, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking.
During the last year, Orexo and Trinity Health have collaborated to establish new administrative processes and support systems to ensure effective patient access to these innovative digital therapies and reimbursement of the products through a collaborative care model. In preparation for the implementation, Orexo and Trinity Health have educated more than 50 healthcare professionals in the collaborative care model, where more traditional healthcare delivery methods are combined with Orexo's digital therapies. To ensure successful implementation, Orexo and Trinity Health have agreed on an extensive communication plan to patients in North Dakota and Eastern Montana.
Both vorvida® and deprexis® are based on cognitive behavioural therapy techniques that empower patients in their efforts to make behaviour and lifestyle changes. These digital therapeutics can be used privately and are available 24 hours a day, helping to reduce the stigma that is often associated with mental illness and substance use disorders (SUD) as well as making evidence-based psychosocial support accessible to a large group of patients.
Trinity Health serves over 25 counties and more than 200,000 people in North Dakota and Eastern Montana, many of whom live in remote areas. According to the Centers for Disease Control and Prevention (CDC), North Dakota has the highest prevalence of binge drinking in the US. CDC data also shows an estimated 25 percent of the adults in North Dakota, and 27 percent of adults in Montana, experienced symptoms of major depressive disorder in July 2022.
Nikolaj Sørensen, President and CEO, said: "I am very pleased to announce that Trinity Health has started to offer our innovative digital therapies, vorvida® and deprexis®, to help patients manage depression and excessive drinking. This milestone is the result of an extensive collaboration with Trinity Health and our shared ambition to be at the forefront in helping people suffering from mental illness and substance misuse. I look forward to continuing our partnership and supporting Trinity Health in becoming a frontrunner among US healthcare systems in making digital therapeutics accessible to patients."
The announcement from Trinity Health can be found at:
https://www.trinityhealth.org/trinity-health-partners-with-orexo-u-s-to-expand-patient-access-to-digital-therapeutics/
For further information, please contact:
Orexo AB (publ.)
Nikolaj Sørensen, President and CEO
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com
About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.
About Trinity Health
Trinity Health is a nonprofit, integrated healthcare system serving northwest and central North Dakota and eastern Montana. There is also a tertiary care hospital in Minot covering more than 40 specialties as well as several rural health clinics and a long-term care facility. Trinity provides a full complement of healthcare services to the region. Since 1922, Trinity has been committed to looking ahead and improving ourselves in ways that provide the best, most compassionate care possible for our patients, families and communities. For more information about Trinity Health please visit, www.trinityhealth.org. You can also follow Trinity Health on Facebook, Instagram, Twitter, LinkedIn and YouTube.
The information was submitted for publication at 4.30 pm CET, on September 7, 2022.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Orexo_Press_release_Trinity Health ND will offer vorvida and deprexis to patients_published Sep 7_ 2022 |
View original content:https://www.prnewswire.com/news-releases/orexos-partner-trinity-health-today-announces-the-availability-of-vorvida-and-deprexis-to-patients-301619430.html
SOURCE Orexo
FAQ
What is the significance of Orexo's partnership with Trinity Health?
How many healthcare professionals were trained for the collaborative care model?
What regions does Trinity Health serve?
Why are vorvida® and deprexis® important for patient care?
What are the statistics on mental health issues in North Dakota?
